Rigel Pharmaceuticals Inc. (New)

RIGLNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
44.48 USD
↗ 0.12 (0.27%)AT CLOSE (11:59 AM EDT)
44.63
↗ 0.15 (0.33%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
44.63
↗ 0.15 (0.33%)
🔴Market: CLOSED

Rigel Pharmaceuticals Inc. (New) (RIGL) is currently trading at $44.58. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (75.7%) and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Sep 16, 2026.

Open?$44.14
High?$45.37
Low?$43.78
Prev. Close?$44.36
Volume?226.4K
Avg. Volume?301.7K
VWAP?$44.87
Rel. Volume?0.75x
Bid / Ask
Bid?$38.18 × 100
Ask?$51.07 × 100
Spread?$12.89
Midpoint?$44.63
Valuation & Ratios
Market Cap?828.6M
Shares Out?18.5M
Float?16.6M
Float %?89.5%
P/E Ratio?2.57
P/B Ratio?1.95
EPS?$17.23
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Targeted Therapy & Precision Oncology
Employees
174
Market Cap
828.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.rigel.com
Listed
2000-11-29
Address
611 GATEWAY BOULEVARD, SUITE 900
SOUTH SAN FRANCISCO, CA 94080
Phone: 650-624-1100
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
89
Momentum?
23
Short Sent.?
25
Piotroski F-Score?2/9Weak
Altman Z-Score?3.81Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?19.22%High
Short Interest?3.2M
Days to Cover?9.1
Free Float16.6M
Avg Daily Volume349.2K
Settlement Date2026-08-31
Financial Health
Current Ratio?1.94Adequate
Quick Ratio?1.79Adequate
Cash Ratio?0.64Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
Peers
100
S&P
97
2.6CHEAP▾
P/B?
Peers
100
S&P
75
1.95CHEAP▾
P/S?
Peers
100
S&P
51
2.99CHEAP▾
P/FCF?
Peers
100
S&P
87
10.4CHEAP▾
EV/EBITDA?
Peers
100
S&P
86
9.0CHEAP▾
EV/Sales?
Peers
100
S&P
62
2.92CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
95
75.7%STRONG▾
ROA?
Peers
50
S&P
97
61.8%STRONG▾
Cash Flow & Enterprise
FCF?$79.4M
Enterprise Value?$807.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist